CTOs on the Move

Health Fuse

www.healthfuse.com

 
Health Fuse is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Hallmark Palm Springs

Hallmark Palm Springs is a Palm Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Electro-Optical Sciences

Electro-Optical Sciences is a Irvington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Massive Bio

Increasing Accessibility to Clinical Trials and Personalized Cancer Treatment Options. Every cancer patient is different and deserves treatment of the highest quality that is personalized, affordable, and easily accessible. Massive Bio translates the world-class oncology knowledge of the large cancer centers​ experts, facilitates a virtual tumor board collaboratively with the treating oncologist, and advises the patient and treating oncologist to operationalize these expert recommendations at the point of care thereby, eliminating additional time, travel, and cost. 85% of US cancer patients receive treatments in community practices where treating oncologists are overwhelmed with the influx of new tests and treatments while trying to manage their busy practices. We believe all cancer patients deserve equal access to the latest in cancer research and treatment.

eloquest healthcare

eloquest healthcare is a Ferndale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.